Knowledge is the power To prevent

GenoRiskDx panel testing uses the latest Next Generation Sequencing (NGS) technology to rapidly analyze patient specimens and provide testing for many hereditary cancer syndromes.

Genetic testing is an important tool for
determining cancer risk.

GenoRiskDx panel testing uses the latest Next Generation Sequencing (NGS) technology to rapidly analyze patient specimens and provide testing for many hereditary cancer syndromes. In total, GenoRiskDx evaluates 38 genes to determine the risk of 18 cancers. Genetic testing can also determine that cancer risks are not increased, if it rules out a known mutation in the family.

Knowing your patient’s cancer risk gives you better ability to provide the most current cancer screening and prevention advice. Sometimes the personal and family history of cancer reveals risk factors for more than one hereditary cancer syndrome. In those cases, panel testing can be efficient and cost-effective.

Genetic testing is now the standard Of care for many patients diagnosed With cancer.

Many of today’s cancer survivors were successfully treated before genetic testing was available. These survivors may be at increased risk for additional cancer, such as ovarian cancer after successful treatment for breast cancer.

Genetic testing is also important for patients with a family history of cancer who do not have a living relative with a cancer history available to undergo testing.

...
What are the signs of hereditary cancer?

Certain cancers are more likely to be hereditary than other cancers. According to the National Comprehensive Cancer Network (NCCN), genetic testing should be offered to all patients with:

  • Ovarian cancer
  • Male breast cancer
  • Medullary thyroid cancer
  • 20 or more colorectal adenomas
...
Other signs of hereditary cancer include:
  • Breast, colon, or endometrial cancer prior to age 50
  • Triple-negative (estrogen, progesterone, Her2neu negative) breast cancer before age 60
  • 2 or more close relatives with the same cancer
  • Multiple primary cancers in the same individual
  • Microsatellite instability (MSI) in colorectal or endometrial tumors

The GenoRiskDx provides a comprehensive report that provides insight into the patient’s specific risk of several types of hereditary cancer.

Research has shown that identifying hereditary cancer risk can be life-saving. Bilateral salpingo-oophorectomy, in particular, has been shown to reduce mortality related to high hereditary ovarian and breast cancer risk.

Cancer Detect Profile

...

Colonoscopy reduces colon cancer mortality but the increased frequency (every 1-2 years) is necessary for people with high hereditary colon cancer risk.

GenoRiskDx reports clearly provide clinically significant data based on the most recent medical literature. Intervention strategies to manage hereditary cancer risk may include:

  • Increased surveillance
  • Chemoprevention
  • Preventative surgery
Card image cap
The ultimate goal of GenoRiskDx is prevention.

GenoRiskDx is a simple in-office test that uses a buccal swab specimen to obtain DNA. We handle patient specimens with the utmost care. Our detailed reports will ensure you provide your patients with the most up-to-date care and best opportunity for cancer prevention.

Insurance coverage: Medicare and most other insurers cover GenoRiskDx for people who meet their testing criteria. The Affordable Care Act (ACA, also known as ObamaCare) mandates most insurers cover breast cancer genetic test counseling and testing for women at higher risk, as well as discussion and chemoprevention for breast cancer. Colonoscopy reduces colon cancer mortality but the increased frequency (every 1-2 years) is necessary for people with high hereditary colon cancer risk.

Genoriskdx provides a comprehensive report that provides insight into the patient’s
the specific risk of several types of hereditary cancer.

Research has shown that identifying hereditary cancer risk can be life-saving. Bilateral salpingo-oophorectomy,
in particular, has been shown to reduce mortality related to high hereditary ovarian and breast cancer risk.

Contact Us
 
Copyright © 2020. Emgenex LLC Terms of Use | Privacy Policy